With the proposed Applied Biosystems-Invitrogen merger set to close in the coming months, ratings firm Fitch Ratings weighed in on the deal this week, giving it mostly a thumbs-up.
In early August, Fitch initiated ratings on Invitrogen with an issuer default rating of BBB-, indicating low credit risk and a stable rating outlook. This week, the firm issued a report providing greater detail about its view of the impending $6.7 billion merger that includes factors influencing its ratings of Invitrogen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.